> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Monitoring Social Media Drug Promotion: Post
- URL: https://www.fdaweb.com/fda-monitoring-social-media-drug-promotion-post/
- Published: 2023-08-29T12:00:00.000Z
- Updated: 2026-09-14T18:53:22.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5155200

Attorneys **Dominic DiSabatino** and **Cortney Inman** (SheppardMullin) say an 8/11 Warning Letter issued by the CDER Office of Prescription Drug Promotion (OPDP) to Exeltis USA over its *Facebook* post for Slynd (drospirenone) oral progestin tablets, demonstrates that OPDP is “closely monitoring social media drug promotion and will respond to clear violations of labeling and advertising regulations.” The attorneys’ online [post](https://www.mondaq.com/unitedstates/food-and-drugs-law/1359638/fdas-office-of-prescription-drug-promotion-issues-second-untitled-letter-of-the-year-to-exeltis-for-misleading-statements-relating-to-slynd%C2%AE?ref=fdaweb.com) says this was only the second OPDP [Warning Letter](https://www.fdaweb.com/opdp-cites-exeltis-promos-on-social-media/) issued this year, both of which cited false and misleading promotional messaging.

“This letter follows a trend of OPDP concentrating on low-hanging fruit,” the attorneys write, “singling out the most noticeable violations that present the greatest concerns for public health. Indeed, this letter is fairly straightforward and underscores some foundational principles of drug advertising and promotion: provide a balanced presentation of safety and risks, and ensure that efficacy claims are consistent with clinical trial data.”

The Warning Letter said Exeltis failed to include any Slynd risk information in its social media post and also failed to submit the promotional material to FDA before it was posted online.